Organ-sparing treatment of advanced bladder cancer: First experience with paclitaxel as alternative to cisplatin

Organ-Sparing Treatment in Muscle-Invasive Bladder Cancer

“…The standard regimen was cisplatin 25 mg/m 2 per day on 5 consecutive days in the 1st and 5th week of radiotherapy (days 1-5 and 29-33) as published recently [17], and 34 patients (50%) were treated according to this regimen. Patients with impaired renal function were either treated with irradiation alone (n = 7) or received paclitaxel as alternative to cisplatin in a phase II protocol or on an individual decision (n = 27); the results of this study have been presented recently [3]. Patients with cisplatin chemotherapy had slightly lower creatinine serum levels prior to treatment than patients who did not received cisplatinum (88.9 ± 20.4 µmol/l vs. 137.5 ± 34.8 µmol/l; p = 0.065).…”

“…There are no randomized studies directly comparing radical cystectomy and such multimodal organ-preserving protocols. However, numerous prospective studies using a bladder-preserving approach have reported survival figures comparable to cystectomy series [3].…”

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer

“…In a poor-risk patient population, paclitaxel was used twice weekly with concomitant RT. All evaluable patients achieved a CR with a 3-year OS of 40% (56). In a phase I–II trial (RTOG 0524), non-surgical elderly patients received paclitaxel (41 patients) with or without transtuzumab (21 patients overexpressing HER2/Neu).…”